- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004487
Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux
OBJECTIVES: I. Determine the safety and efficacy of chondrocyte alginate gel suspension in pediatric patients with vesicoureteral reflux.
II. Determine the long term efficacy of this treatment regimen in this patient population.
III. Evaluate the short and long term avoidance of surgery or antibiotic therapy after this treatment regimen in this patient population.
IV. Estimate the risk:benefit ratio of this treatment regimen in these patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PROTOCOL OUTLINE: This is a multicenter study. Patients undergo biopsy of the auricular cartilage for chondrocytes during cystoscopic evaluation on day 1. Chondrocyte alginate gel suspension is injected into the submucosa of the bladder at the vesicoureteral junction between days 40-50. Patients found to have post treatment reflux may be retreated once.
Patients are followed at 1, 3, and 12 months.
Study Type
Enrollment
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Confirmed grade 3 or 4 reflux in at least one ureter by voiding cystourethrogram Breakthrough urinary tract infection despite standard antibiotic therapy OR Persistent reflux unlikely to resolve spontaneously
- Grade 3: 2 year reflux duration OR 1 breakthrough infection Grade 4: 1 year reflux duration OR 1 breakthrough infection
- Coexisting grade 1 or 2 reflux OR Resolved reflux (i.e., contralateral to the existing grade 3 or 4 refluxing ureter) allowed
- No reflux secondary to obstruction or neuropathic disease
- No gross urological abnormalities (e.g., megaureter requiring ureteral tapering or duplicity of ureters)
--Prior/Concurrent Therapy--
- Surgery: No prior surgery for correction of reflux No recent prior urological device implantation
--Patient Characteristics--
- Hematopoietic: No history of bleeding disorders
- Cardiovascular: No history of hypertension or cardiac disease
- Pulmonary: No history of pulmonary disease
- Other: No known allergies to contrast dyes, iodine, or shellfish No contraindications to general anesthesia No prior infections (other than UTIs) No immunodeficiencies No metabolic disease No social situation that would interfere with follow up Not pregnant Negative pregnancy test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Frank T. Gentile, Curis, Inc.
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/14267
- REPRO-FDR001514
- REPRO-99-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vesicoureteral Reflux
-
St. Luke's Medical Center, PhilippinesCompletedUrinary Tract Infection | Vesicoureteral Reflux (VUR)Philippines
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Johns Hopkins UniversityTerminatedVesicoureteral RefluxUnited States
-
Stanford UniversityLucile Packard Children's HospitalCompleted
-
TC Erciyes UniversityCompletedVesicoureteral Reflux | Nipple UreteroneocystostomyTurkey
-
Stanford UniversityCompletedVesicoureteral RefluxUnited States
-
Washington University School of MedicineSociety of Pediatric UrologyTerminatedVesicoureteral RefluxUnited States
-
Connecticut Children's Medical CenterCompleted
-
Boston Children's HospitalWithdrawnVesicoureteral RefluxUnited States
-
Samsung Medical CenterCompletedVesicoureteral RefluxKorea, Republic of
Clinical Trials on chondrocyte-alginate gel suspension
-
Queen Elizabeth Hospital, Hong KongThe Hong Kong Polytechnic UniversityCompletedDiabetic Foot
-
Rhodes Pharmaceuticals, L.P.ORA, Inc.Completed
-
Reckitt Benckiser Healthcare (UK) LimitedCompletedGastro-esophageal Reflux Disease (GERD)China
-
Reckitt Benckiser Healthcare (UK) LimitedTerminatedGastro-esophageal Reflux Disease (GERD)China
-
Chulalongkorn UniversityCompletedHeartburn in PregnancyThailand
-
Pamukkale UniversityCompleted
-
Aditya K AggarwalPostgraduate Institute of Medical Education and ResearchUnknownOsteoarthritis, KneeIndia
-
LEO PharmaCompletedScalp PsoriasisUnited States
-
Columbia UniversityActive, not recruitingSepsis | Critical Illness | Nutrition Disorders | Antibiotic Resistant Infection | Nosocomial Infection | Pathogen TransmissionUnited States
-
LEO PharmaCompletedScalp PsoriasisCanada, United Kingdom, France